• We The Patients Fly-In
  • Events Calendar
0 Items
Patients Rising Now
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
  • Donate
Select Page
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
  • Donate

Featured

Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20

Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20

May 23, 2022 | Drug Costs, Featured, Podcast

On this episode of the podcast, Terry and Bob discuss a new effort by entrepreneur Mark Cuban to deliver less expensive medications to patients. They also explain the ongoing baby formula shortage plaguing the country and point out how the industry’s...
Read more
Have Health Plans Abandoned Rare Disease Patients?: Season 3 | Episode 19

Have Health Plans Abandoned Rare Disease Patients?: Season 3 | Episode 19

May 17, 2022 | Featured, Health Insurance, Podcast

On this episode of the podcast, Terry and Bob discuss health access challenges facing patients with rare diseases on employer health plans. They point out new data on drug rebates showing no relationship between the size of rebates and drug price savings. And they...
Read more
Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021

Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021

May 16, 2022 | Featured, Letters Submitted

We appreciate the work of the Senate Committee on Health, Education, Labor, and Pensions (HELP) in reauthorizing the Food and Drug Administration’s (FDA) user fee programs for generic drugs (GDUFA). The improvements in GDUFA III will speed patient access to safe,...
Read more
OIG Report Tags Biosimilars for Medicare and Beneficiary Savings

OIG Report Tags Biosimilars for Medicare and Beneficiary Savings

May 13, 2022 | Featured, Health Policy

Surabhi Dangi-Garimella, Ph.D. Despite biosimilars being around for a while, utilization in the U.S. has not caught on. Several studies have shown the cost benefit of replacing originator or reference products with biosimilars; however, contracts between drug...
Read more
Urge the FTC to study the perverse practices of Pharmacy Benefit Managers (PBMs)

Urge the FTC to study the perverse practices of Pharmacy Benefit Managers (PBMs)

May 11, 2022 | Actions, Featured, Featured Action, Pharmacy Benefit Managers

Urge the FTC to study the perverse practices of Pharmacy Benefit Managers (PBMs) On February 24, the Federal Trade Commission (FTC) issued a solicitation for comment regarding Pharmacy Benefit Managers (PBMs) and the impact PBMs have on patients, among others. You can...
Read more
Updates from the Frontlines of Medical Research – Season 3 | Episode 18

Updates from the Frontlines of Medical Research – Season 3 | Episode 18

May 9, 2022 | Featured, Podcast

On this episode of the podcast, Terry and Bob discuss the latest medical research into ALS in conjunction with ALS Awareness Month. Dr. Sharon Hesterlee, the Chief Research Officer at the Muscular Dystrophy Association, joins the show to give the big picture on ALS...
Read more
« Older Entries

Categories

  • Access
  • Actions
  • California
  • Copay Accumulators
  • Copay Assistance
  • COVID-19
  • Drug Costs
  • FDA
  • Featured
  • Featured Action
  • Federal Issues
  • Health Insurance
  • Health Policy
  • ICER
  • Illinois
  • Issues
  • Letters Submitted
  • Letters Supported
  • Massachusetts
  • Medicaid
  • Medicare
  • Medicare Part D
  • News
  • Op-Ed
  • Out of Pocket Costs
  • Pharmacy Benefit Managers
  • Podcast
  • Prescription Drugs
  • Press Releases
  • Public Statement
  • QALY
  • State Issues
  • Statements
  • Step Therapy
  • Surprise Billing
  • Terry's Hot Take
  • Uncategorized
  • Value Based Insurance Design
  • Value Frameworks
  • Virtual Advocacy Chat

Tags

21st Century Cures Act 340B Access to Care Advocacy Alzheimer's Biden Administration biosimilars Cancer cms Copay Accumulators copay assistance COVID-19 Vaccine drug costs Drug Manufacturing Drug Pricing drug rebate fail first FDA H.R.3 Healthcare Inequities Health Insurance hospital bills HR 3708 hsa ICER Insurance design Joe Biden Lupus medicare Part B medicare part D Mental Health Nonmedical Switching open enrollment Out of Pocket Costs PBM pharmacy benefit managers Price Transparency Prior Authorization QALY Rare Disease Right to Repair Step Therapy Telehealth transparency Value Framework

Recent Posts

  • Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20
  • What is the Future of Co-pay Accumulator and Maximizer Programs? 
  • Have Health Plans Abandoned Rare Disease Patients?: Season 3 | Episode 19
  • Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021
  • OIG Report Tags Biosimilars for Medicare and Beneficiary Savings

Sign up for updates

Patients Rising Now

We are a 501c4 group dedicated to demanding transparency in health care.  We are part of the Patients Rising suite of programs and services.

700 12th St. NW 700, Suite 700
Washington, DC 20005

  • Privacy Policy
  • Sponsor Opportunities
  • Patients Rising
  • Facebook
  • Twitter
  • Instagram
All rights reserved. © 2022 Patients Rising Now